Introduction Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory illness in infants and young children. Each year, RSV leads to numerous hospitalizations worldwide, especially in babies under 6 months of age. While vaccines for older adults and pregnant women help protect some populations, infants themselves can now be directly protected through Beyfortus (nirsevimab), a monoclonal antibody specifically designed for RSV prevention. Beyfortus represents a major advance in infant care, offering passive immunity during the first months of life, when babies are most vulnerable to severe RSV complications. What is Beyfortus? Beyfortus is a long-acting monoclonal antibody that…